MLTX MoonLake Immunotherapeutics
Price Chart
Executive Summary
MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and Capacity Agreement with Vetter Pharma for commercial manufacturing of pre-filled devices for its lead candidate sonelokimab. The agreement includes binding minimum and maximum capacity commitments but no financial terms were disclosed. This is a routine operational step forward for the company as it prepares for potential commercial launch.
Actionable Insight
Monitor for future product schedules that will reveal pricing and volume details, as well as regulatory updates on sonelokimab that could affect commercial launch timing and demand for manufacturing capacity.
Key Facts
- Entered into Master Commercial Supply Agreement with Vetter Pharma International GmbH for manufacturing of pre-filled application systems for sonelokimab.
- Simultaneously signed a Capacity Agreement with binding minimum quantity commitments and a maximum quantity cap.
- Product-specific pricing and terms will be detailed in future schedules under the master agreement.
- Termination provisions include change-of-control clauses and 12-month notice for no-cause termination.
Financial Impact
No financial terms disclosed; capacity commitments may carry compensation obligations if minimum orders not met.
Risk Factors
- Capacity commitment could become a financial burden if sonelokimab fails to gain regulatory approval or commercial traction.
- No financial terms disclosed, making it difficult to assess potential impact on operating expenses.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063125 |
| Document: 0001213900-26-063125-index-headers.html | 0001213900-26-063125 |
| Document: 0001213900-26-063125-index.html | 0001213900-26-063125 |
| Document: 0001213900-26-063125.txt | 0001213900-26-063125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $17.99 awaiting T+5 | awaiting T+5 | — | $18.69 (−3.89%) |
|
Jun 1, 2026
13d ago
|
8-K
| $18.82 $17.90 | ▼ −4.89% | ▼ −2.14% | $18.69 (−0.69%) |
|
May 10, 2026
5w ago
|
Press Release
| $18.84 $16.44 | ▼ −12.74% | ▼ −12.65% | $18.69 (−0.80%) |
|
Apr 1, 2026
10w ago
|
144
| $16.52 $19.41 | ▼ −17.49% | ▼ −13.73% | $18.69 (−13.14%) |
|
Mar 28, 2026
11w ago
|
Press Release
| $16.93 $17.08 | ▲ +0.89% | ▼ −3.41% | $18.69 (+10.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access